截至2025年8月25日收盘，赛诺医疗股价报33.38元，较前一交易日上涨0.68元，涨幅2.08%。当日成交 额23.07亿元，换手率16.47%。 赛诺医疗属于医疗器械行业，专注于高端介入医疗器械的研发、生产和销售。公司主要产品包括冠脉支 架、球囊导管等，其控股子公司赛诺神畅医疗科技有限公司近日获得国家药监局颁发的一次性使用微导 管医疗器械注册证，该产品适用于神经血管内操作。 风险提示：市场有风险，投资需谨慎。 来源：金融界 消息面上，赛诺医疗公告称，其子公司获得一次性使用微导管注册证，注册证有效期至2030年8月21 日。此外，公司2025年中期实现营收2.40亿元，归母净利润1384万元。 资金流向方面，8月25日主力资金净流出1.07亿元，近五日主力资金累计净流出14.54亿元。 ...

Group 1 - The stock price of Sino Medical reached 30.40 yuan as of August 14, 2025, marking a 3.05% increase from the previous trading day [1] - The trading volume on that day was 2.26 billion yuan, with a turnover rate of 18.55% [1] - Sino Medical specializes in the research, production, and sales of cardiovascular interventional medical devices, including coronary stents and balloon catheters [1] Group 2 - A subsidiary of Sino Medical recently received recognition from the U.S. Food and Drug Administration (FDA), which has generated market interest in its potential applications in the field of neurovascular intervention [1] - On August 14, the net inflow of main funds was 164 million yuan, accounting for 1.3% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds was 143 million yuan [1]

Group 1 - The stock price of Sino Medical reported at 14.19 yuan as of August 6, 2025, down by 2.54% from the previous trading day [1] - The trading volume on that day was 119,538 hands, with a transaction amount of 171 million yuan [1] - Sino Medical operates in the medical device industry, focusing on the research, production, and sales of high-end interventional medical devices, including cardiovascular interventional devices like stents and balloon catheters [1] Group 2 - The company's subsidiary, Sino Shenchang, specializes in the development of products in the neurointerventional field [1] - Sino Shenchang's COMETIU self-expanding intracranial drug-coated stent system and COMEX balloon microcatheter have received breakthrough medical device designation from the FDA [1] - This product is the first in FDA history for the treatment of intracranial atherosclerotic stenosis and the first domestically produced neurointerventional device to receive such designation [1] Group 3 - On the funding flow side, there was a net outflow of 28.91 million yuan from main funds on that day, accounting for 0.49% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds reached 33.18 million yuan, representing 0.56% of the circulating market value [1]